VAV1 as a putative therapeutic target in autoimmune and chronic inflammatory diseases
Neurath M, Berg LJ (2024)
Publication Type: Journal article, Review article
Publication year: 2024
Journal
Book Volume: 45
Pages Range: 580-596
Journal Issue: 8
Abstract
The guanine nucleotide exchange factor (GEF) VAV1, a previously ‘undruggable’ protein integral to T/B lymphocyte antigen–receptor signaling, promotes actin polymerization, immunological synapse formation, T cell activation and differentiation, and cytokine production. With the development of novel modalities for targeting proteins, we hypothesize that interventions targeting VAV1 will have therapeutic potential in T and T/B cell-mediated autoimmune and chronic inflammatory diseases. This opinion is supported by recent CRISPR-Cas9 studies showing VAV1 as a key positive regulator of T cell receptor (TCR) activation and cytokine production in primary human CD4+ and CD8+ T cells; data demonstrating that loss/suppression of VAV1 regulates autoimmunity and inflammation; and promising preclinical data from T and T/B cell-mediated disease models of arthritis and colitis showing the effectiveness of selective VAV1 targeting via protein degradation.
Authors with CRIS profile
Involved external institutions
United States (USA) (US)How to cite
APA:
Neurath, M., & Berg, L.J. (2024). VAV1 as a putative therapeutic target in autoimmune and chronic inflammatory diseases. Trends in Immunology, 45(8), 580-596. https://doi.org/10.1016/j.it.2024.06.004
MLA:
Neurath, Markus, and Leslie J. Berg. "VAV1 as a putative therapeutic target in autoimmune and chronic inflammatory diseases." Trends in Immunology 45.8 (2024): 580-596.
BibTeX: Download